Introduction {#Sec1}
============

The accuracy of the clinical diagnosis of melanocytic skin lesion is limited. Conventional clinical diagnosis of melanoma based on ABCD criteria (A asymmetry, B irregular borders, C various colors, D diameter \>6 mm) is reliable only in approximately 60% of cases and excludes small melanomas (\<6 mm). In addition, very early melanomas may have a regular shape and homogeneous color \[[@CR1], [@CR3], [@CR13], [@CR14]\]. Dermoscopy (epiluminescence microscopy, surface microscopy, and dermatoscopy) allows the identification of common and dysplastic nevi and also increases the diagnostic accuracy in cases of malignant melanomas \[[@CR4], [@CR7], [@CR25], [@CR26]\]. Its value in early and differential diagnosis of cutaneous melanoma has been clearly established by two independent meta-analyses, and efficient diagnostic algorithms have been published \[[@CR6], [@CR15]\]. Although dermoscopy has been introduced worldwide, it does not include evaluation of lesions at cellular level, which could enhance diagnostic accuracy for melanocytic skin lesions \[[@CR13]\].

The regulation of cell proliferation is crucial for normal development, pathophysiological responses to injury, and tumorigenesis. Progression through the cell cycle is controlled by cyclins, cyclin-dependent kinases, and inhibitory proteins. D-type cyclins (D1 and D3) are the first cyclins to be expressed in the G1 phase and bound to their kinases CDK4 and CDK6. They play a major role in progression through the G1 restriction point \[[@CR10], [@CR12], [@CR20]\] by regulating the function of pRb (retinoblastoma protein), which in its hypophosphorylated form (the functionally active form) can arrest cell cycle in G1 \[[@CR12]\].

The role of cyclin D1 in the development, progression, and prognosis of melanomas is controversial. Some authors reported no difference in its expression in nevi and melanomas, whereas others showed overexpression of this protein in melanomas \[[@CR10], [@CR20]\]. Cyclin D3 is an important regulator of melanoma G1-S cycle progression. Its expression in melanoma cells can be readily detected by immunohistochemistry and is associated with poor prognosis \[[@CR22]\].

It was proved that cyclin D1 increases cell growth potential and has no influence on cell differentiation \[[@CR19]\]. Recent data suggest that cyclin D1 could be a marker of dysplastic skin lesions as it was overexpressed within the dermal--epidermal junction and/or papillary dermis in dysplastic nevi \[[@CR9]\]. Cyclin D3, on the other hand, has been shown to have a dual function in proliferation and differentiation \[[@CR17]\], and cyclin D3-positive cells were present throughout the lesion in most malignant melanomas, showing a close association between its expression and proliferation in superficial spreading melanomas \[[@CR10]\].

The clinical and histopathological features allow to discriminate common nevi from melanomas; however, discrimination between dysplastic nevi and melanomas can be sometimes problematic, and the histologic criteria for diagnosis of the former are still disputed \[[@CR11]\]. Hence, in doubtful cases, an additional diagnostic marker would be helpful. Studies of cyclin expression compared melanocytic nevi and melanomas \[[@CR10], [@CR12]\], but dysplastic nevi were not included in the analysis as a separate group. Therefore, the aim of the present study was to evaluate cyclin D1 and D3 expression in three groups of melanocytic lesions: common nevi, dysplastic nevi, and malignant melanomas and determine whether it could serve as a diagnostic marker in histologically uncertain lesions.

Materials and methods {#Sec2}
=====================

Dermoscopy {#Sec3}
----------

Forty-eight melanocytic skin lesions were collected from patients at the Department of Dermatology, Jagiellonian University Medical College, Krakow, Poland. The study was approved by the Ethics Committee of the University in May 2008. Written informed consent was obtained from each patient following the guidelines of the Helsinki Declaration. The lesions were diagnosed by dermoscopy using Minolta Derlite photodermoscope. Surgical excision of melanocytic skin lesions for histopathologic evaluation is recommended when the lesion shows one of the following clinical or dermoscopic features: (1) benign dermal papillomatous nevus located in highly traumatic area, (2) the presence of two out of three criteria of the 3-point checklist as a screening method (1 asymmetry, 2 atypical network, and 3 blue-white structures) \[[@CR25]\]), (3) the presence of one or two melanoma-specific local criteria (atypical pigment network, irregular streaks, irregular dots and globules, irregular blotches, and blue-white structures). Lesions fulfilling the above criteria were excised; in case of melanomas, the margin of normal skin (used as control samples) depended on the thickness of melanoma: for melanoma in situ---5 mm; for thickness \<2 mm---1 cm; and for thickness \>2 mm---2 cm. The samples collected were common nevi (10), dysplastic nevi (24), and melanomas (14), including nodular melanoma (7), superficial spreading melanoma (3), and lentigo maligna melanoma (4). Among the melanoma cases, six samples were defined as "thin", with Breslow thickness \<1 mm, and eight samples as "thick" with Breslow thickness \>1 mm. None of the patients with melanoma had metastases.

Histopathology and immunohistochemistry {#Sec4}
---------------------------------------

The excised samples were fixed in 10% buffered formalin and embedded in paraffin. All lesions were evaluated using the standard histopathologic criteria (hematoxylin and eosin-stained sections) to reconfirm the diagnosis. The histologic identification of dysplastic nevi was based on the presence of junctional nests of melanocytes often exhibiting large pleomorphic nuclei and prominent nucleoli, uniformly elongated rete ridges, and lymphocytic infiltrations \[[@CR11]\].

In three cases, dermoscopic diagnosis was altered after histopathologic evaluation: two dermoscopically diagnosed melanomas were identified as dysplastic nevi, and one dermoscopically diagnosed superficial spreading melanoma was identified as lentigo maligna melanoma.

For immunohistochemistry, deparaffinized 6 μm sections were subjected to antigen retrieval using 10 mM citrate buffer, pH 6.0 (5 min preincubation followed by 9 min in microwave oven, 160 W, at 100°C, and 30 min in vapor bath at 80°C). Next the sections were incubated overnight at 4°C with primary mouse antibodies against cyclin D1 or D3, followed by secondary goat anti-mouse Cy3-conjugated antibody. The antibodies were diluted according to manufacturer's recommendations (Table [1](#Tab1){ref-type="table"}). Cell nuclei were counterstained with DAPI (Sigma, Saint Louis, MO, USA). Only nuclear immunostaining was scored as positive. In each sample, cyclin expression was assessed as percentage of cyclin-positive nuclei in the examined lesion. Microscopic examination, digital imaging of sections, and image analysis were carried out using Olympus BX-50 bright field/epifluorescence microscope equipped with DP-71 camera (Olympus, Japan) and PC-based image analysis software (AnalySIS-FIVE^®^, Soft Imaging System GmbH, Münster, Germany).Table 1Antibodies used in the studyAntibody againstSupplierCodeDilutionPrimary antibodies Cyclin D1Novocastra Laboratories Ltd., Newcastle, UKNCL-CYCLIN D11:20 Cyclin D3Novocastra Laboratories Ltd., Newcastle, UKNCL-CYCLIN D31:20Secondary antibodies Goat anti-mouse, Cy-3-conjugatedJackson IR, West Grove, PA, USA115-165-1461:400

Statistical analysis {#Sec5}
--------------------

The relationship between expression of cyclins and the type of melanocytic skin lesion (common nevi, dysplastic nevi, melanoma) was evaluated by nonparametric ANOVA rank Kruskal--Wallis test with *p* \< 0.05 as condition for statistical significance.

Results {#Sec6}
=======

In normal skin, the expression of cyclins D1 and D3 was not detected. In melanocytic lesions, immunostaining was observed in cell nuclei, with some cells also exhibiting very weak cytoplasmic staining (Fig. [1](#Fig1){ref-type="fig"}). In common nevi, cyclin D1 and D3 immunostaining was observed mainly in cells located near the dermal--epidermal junction, whereas dysplastic nevi and melanomas exhibited a uniform distribution of cyclin-positive cells.Fig. 1Micrographs showing cyclin D3 expression (dim red nuclear immunofluorescence) in common nevus (**a**), dysplastic nevus (**b**), and melanoma (**c**). Note weak signals emitted by three nuclei in common nevus and gradually increasing number of immunopositive nuclei in dysplastic nevus and melanoma. *DAPI* counterstaining of cell nuclei, *bright orange* nonspecific fluorescence of red blood cells. Original magnification ×400

All investigated lesion samples showed expression of both cyclins. The mean percentage of cyclin D1-positive nuclei in melanomas, dysplastic nevi, and common nevi were 7.75, 5, and 0.34%, respectively. The corresponding percentages for cyclin D3 were 17.8, 6.4, and 1.08% (Table [2](#Tab2){ref-type="table"}). Scoring data are shown in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}. Statistically significant differences in cyclin D1 expression were observed between melanomas and common nevi and between dysplastic and common nevi (*p* = 0.0001), but not between dysplastic nevi and melanomas. Significant differences in cyclin D3 expression were observed between all lesion types: between melanomas and dysplastic nevi, between melanomas and common nevi and between dysplastic and common nevi (*p* = 0.0000; Table [2](#Tab2){ref-type="table"}). The mean cyclin D1 and D3 scores of melanomas with Breslow thickness \<1 mm were not significantly different from those of melanomas with Breslow thickness \>1 mm (Figs. [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}).Table 2Differences in cyclin D1 and D3 expression in melanocytic skin lesionCyclin D1Melanomas *R* (7.75%)Dysplastic nevi *R* (5%)Common nevi *R* (0.34%)Melanomas1.9697364.322768\*Dysplastic nevi1.9697362.995276\*Common nevi4.322768\*2.995276\*Cyclin D3Melanomas *R* (17.8%)Dysplastic nevi *R* (6.4%)Common nevi *R* (1.08%)Melanomas2.739677\*4.478033\*Dysplastic nevi2.739677\*2.478140\*Common nevi4.478033\*2.478140\*Cyclin D1: Kruskal--Wallis test: H (2, *N* = 48) = 18,77577, \* significant, *p* = 0.0001Cyclin D3: Kruskal--Wallis test: H (2, *N* = 48) = 20,32182, \* significant, *p* = 0.0000*R* mean percentage of immunostained cell nucleiFig. 2Cyclin D1 expression (percentage of immunostained cell nuclei) in melanocytic lesionsFig. 3Cyclin D3 expression (percentage of immunostained cell nuclei) in melanocytic lesionsFig. 4Cyclin D1 expression (percentage of immunostained cell nuclei) in melanomas according to tumor thicknessFig. 5Cyclin D3 expression (percentage of immunostained cell nuclei) in melanomas according to tumor thickness

Discussion {#Sec7}
==========

In the present study, dermoscopy was employed to identify melanocytic skin lesions: common nevi, dysplastic nevi, and melanomas. We excised common nevi only if they were located in a highly traumatic area; patients were worried about their possible malignant transformation and insisted on their removal. Since the dysplastic nevi can be an intermediate step in tumor progression from common acquired melanocytic nevi to melanomas \[[@CR2], [@CR21]\], we excised them in cases when the dermoscopic appearance of the nevus did not allow to exclude melanoma with certainty.

In the three types of melanocytic skin lesions, immunohistochemistry was used to evaluate the expression of cyclins D1 and D3. These cyclins, belonging to G1 cyclin family, are important for the passage of cells through the G1 phase into the S phase. We found the same expression pattern for both cyclins: expression was the highest in melanomas, the lowest in the common nevi, and intermediate in the dysplastic nevi, with all differences statistically significant except that between melanomas and dysplastic nevi for cyclin D1. Coordinated expression of both cyclins in dysplastic nevi and malignant tumors indicates that more than one D-type cyclin may be involved in tumor development.

Although no cyclin D1 expression could be detected in normal skin areas, we observed very few (0.34%) cyclin D1-positive cell nuclei in common nevi, in contrast to data reported by other authors who failed to find cyclin D1 expression in any common nevi \[[@CR10]\]. Cyclin D1-positive cells were mostly located close to the dermal--epidermal junction, which corresponds to the observations of Stefanaki et al. \[[@CR23]\] that common nevi shows either rare cyclin D1 positivity or a zonal expression pattern. This is quite distinct from melanomas which display diffuse cyclin D1 expression.

Previous studies have demonstrated various abnormalities in cyclin D1 and D3 expression in sporadic and familial melanomas \[[@CR10], [@CR12], [@CR20], [@CR24]\]. Cyclin D1 was observed to be recurrently overexpressed in melanomas, and its downregulation had a significant impact on melanoma cell growth \[[@CR23]\]. We found significantly higher cyclin D1 expression in melanomas compared with common nevi, suggesting that cyclin D1 may play a role in the development of the malignant phenotype. Some authors reported the same relationship between common nevi and malignant melanocytic tumors, but others found no significant differences in the expression of cyclin D1 between those two groups \[[@CR12], [@CR20]\].

Cyclin D3 expression is required for efficient G1-S cell cycle progression, proliferation, and differentiation of melanocytes \[[@CR5], [@CR18], [@CR22]\]. We found significantly higher cyclin D3 expression in melanomas as compared with dysplastic nevi. In case of cyclin D1, the difference also existed, but did not reach the level of significance. However, dysplastic nevi revealed significantly higher expression of both cyclins as compared with common nevi. It corresponds to results reported by Ewanowich et al. \[[@CR9]\] who found overexpression of cyclin D1, especially in the region of epidermal--dermal junction. Enhanced cyclin expression in dysplastic nevi supports the view that cyclins are activated during the transition from benign to malignant phenotype of melanocytic skin lesion, and that dysplastic nevi represents an intermediate stage in this process. Our findings also suggest that cyclin D3 expression could be a marker for dysplastic melanocytic lesions in histopathologically ambiguous lesions, being significantly lower than in melanomas.

No relationship between thickness of melanoma and cyclin D1 and D3 expression observed in the present study seems to be a controversial finding. In case of cyclin D1, it remains in agreement with previous data reported in the literature \[[@CR12], [@CR20]\] although, in a recent study, de Sa et al. \[[@CR8]\] demonstrated higher expression of cyclin D1 in thin superficial spreading melanomas as compared to thick ones. In case of cyclin D3, the results of other studies are discrepant: its expression was found to be higher in thicker superficial spreading melanomas, while the opposite relation was observed in nodular melanomas \[[@CR10]\]. Jørgensen et al. \[[@CR16]\] reported an association between cyclin D3 expression, cell proliferation, and disease progression in superficial spreading melanomas, and also observed higher expression being significantly associated with the thickness of primary tumors. We could not find any significant association between melanoma thickness and cyclin expression, possibly because of relatively small number of melanoma samples.

In summary, the present study has confirmed that G1/S abnormalities are crucial in the progression of melanocytic skin lesions, and that deregulation of cyclin D1 and D3 expression leading to increased melanocyte proliferation points to candidate proteins involved in melanoma genesis as possible therapeutic targets. Cyclin D3, showing significantly lower expression in dysplastic nevi than in melanomas, but higher than in common nevi, seems to be a suitable diagnostic marker for differentiation of these lesions in histologically doubtful cases.
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